Targeting Low HDL-Cholesterol to Decrease Residual Cardiovascular Risk in the Managed Care Setting

Authors:
  • MCMark J. Cziraky
    Mark J. Cziraky
  • KWKarol E. Watson
    Karol E. Watson
  • RTRobert L. Talbert
    Robert L. Talbert

Abstract
BACKGROUND: Most clinicians recognize the importance of reducinglow-density lipoprotein cholesterol (LDL-C) and, therefore, address thistherapeutic need to decrease cardiovascular disease risk. In addition to thecritical role that LDL-C plays, recent studies have shown the contribution ofother lipid fractions, such as high-density lipoprotein cholesterol (HDL-C)and triglycerides (TG), to overall cardiovascular health. Managed careinitiatives to reduce cardiovascular risk typically focus on highly effectivestatin therapies, which are primarily LDL-C-lowering agents and have lesserTG-lowering and HDL-C-raising effects. However, clinical and epidemiologicdata illustrate the need to expand the scope of therapies to reduce theresidual cardiovascular risk associated with low HDL-C levels and elevatedTG levels, even when LDL-C is managed successfully. OBJECTIVE: To address the value of treating beyond LDL-C level to improvepatient health outcomes and reduce health care-related costs. SUMMARY: Several large trial...